Verdiperstat - Biohaven Pharmaceutical Holding Company

Drug Profile

Verdiperstat - Biohaven Pharmaceutical Holding Company

Alternative Names: AZD 3241; BHV3241

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biohaven Pharmaceutical Holding Company
  • Class Antiparkinsonians; Pyrimidinones; Small molecules
  • Mechanism of Action Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple system atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple system atrophy
  • Discontinued Parkinson's disease

Most Recent Events

  • 05 Sep 2018 AZD 3241 (now BHV 3241) licensed to Biohaven Pharmaceutical Holding Company worldwide for the treatment of neurological disorders, including Multiple system atrophy
  • 05 Sep 2018 Phase-II clinical trials in Multiple system atrophy in USA (PO)
  • 05 Sep 2018 Efficacy data from a phase IIa trial in Multiple system atrophy released by Biohaven Pharmaceutical Holding Company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top